Likely cancer case surge raises health system worries
More than 4.5 million new cancer cases are projected to be diagnosed in Australia before 2044, according to research from peak independent authority Cancer Council Australia.
A survey of more than 1500 Australians found almost half believed the nation's health system was unprepared for this rise in cases.
More than 70 per cent said they were concerned about developing cancer in their lifetime.
Young Australians were particularly worried, with 80 per cent of those aged 25 to 34 saying they were concerned about their cancer risk.
While cancer risk increased with age, Cancer Council policy director Megan Varlow said governments could do more to safeguard young people's future health.
"We know that 42 per cent of the total cancer burden is attributed to modifiable risk factors such as overweight and obesity, insufficient physical inactivity and UV exposure, all areas where prevention measures can make a significant difference," she said.
"While prevention is key to reducing cancer rates, we need to recognise that nearly one in two Australians will be affected by cancer in their lifetime."
The council is calling on the incoming federal government to commit to four key priorities to reduce the impact of cancer for all Australians.
This includes tackling the rise of obesity, investing in skin cancer prevention campaigns, increasing participation in the national bowel cancer screening program and providing equitable access to cancer care through improved services and support.
"Australians deserve to live healthy lives now and into the future," Ms Varlow said.
"This means having easy access to healthy foods to feed their families, living in environments that promote physical activity ... (and) feeling confident in looking after their health by protecting their skin from the sun or by taking a cancer screening test."
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 hours ago
- Yahoo
US Vaccine Fatigue Will Fade, CSL CEO Says
CSL CEO and Managing Director Paul McKenzie says the time is right to spin off its Seqirus business as vaccine demand grows and "fatigue" fades in the US, especially among the ageing population. The Australian biotech giant's shares plunged the most in 23 years after it reported disappointing earnings. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
4 hours ago
- Yahoo
ASX Penny Stocks Spotlight: Berkeley Energia And 2 Other Noteworthy Picks
Australian shares are experiencing a downturn, with the ASX 200 futures showing a slight decline amid cautious sentiment surrounding the government's Economic Reform Roundtable and reactions to Wall Street's recent highs. In such uncertain market conditions, investors often look beyond established names to explore opportunities in smaller or newer companies. Penny stocks, despite being considered an outdated term, continue to intrigue investors with their potential for growth at lower price points. Top 10 Penny Stocks In Australia Name Share Price Market Cap Financial Health Rating Alfabs Australia (ASX:AAL) A$0.45 A$124.67M ★★★★☆☆ EZZ Life Science Holdings (ASX:EZZ) A$2.49 A$117.93M ★★★★★★ GTN (ASX:GTN) A$0.4025 A$77.22M ★★★★★★ IVE Group (ASX:IGL) A$2.965 A$461M ★★★★★☆ West African Resources (ASX:WAF) A$2.715 A$3.09B ★★★★★★ Regal Partners (ASX:RPL) A$3.10 A$1.05B ★★★★★★ Bravura Solutions (ASX:BVS) A$2.08 A$927.98M ★★★★★★ Austco Healthcare (ASX:AHC) A$0.37 A$137.06M ★★★★★★ Bisalloy Steel Group (ASX:BIS) A$4.51 A$218.27M ★★★★★★ CTI Logistics (ASX:CLX) A$1.855 A$149.41M ★★★★☆☆ Click here to see the full list of 450 stocks from our ASX Penny Stocks screener. Let's review some notable picks from our screened stocks. Berkeley Energia Simply Wall St Financial Health Rating: ★★★★★★ Overview: Berkeley Energia Limited focuses on the exploration and development of mineral properties in Spain with a market capitalization of A$245.19 million. Operations: Currently, the company does not report any revenue segments. Market Cap: A$245.19M Berkeley Energia, with a market cap of A$245.19 million, is currently pre-revenue and focuses on mineral exploration in Spain. The company has transitioned to profitability this year and maintains a debt-free status, contrasting its previous debt to equity ratio of 55.3% five years ago. Its seasoned board and management team bring significant experience, with average tenures of 13.3 and 9.8 years respectively. Despite low Return on Equity at 1.2%, Berkeley's strong asset position covers both short-term (A$80.1M) and long-term liabilities (A$1.8M), while shareholders have not faced meaningful dilution recently. Click here and access our complete financial health analysis report to understand the dynamics of Berkeley Energia. Review our historical performance report to gain insights into Berkeley Energia's track record. Core Lithium Simply Wall St Financial Health Rating: ★★★★★☆ Overview: Core Lithium Ltd focuses on developing lithium and various metal deposits in Northern Territory and South Australia, with a market cap of A$278.59 million. Operations: The company's revenue is primarily generated from the Finniss Lithium Project, contributing A$52.28 million. Market Cap: A$278.59M Core Lithium, with a market cap of A$278.59 million, is focused on developing lithium projects in Australia and generated A$52.28 million from its Finniss Lithium Project. The company remains unprofitable and is not expected to achieve profitability in the next three years despite revenue growth forecasts of 39.2% annually. Core Lithium has a stable financial position with short-term assets (A$60.7M) exceeding both short-term (A$32.5M) and long-term liabilities (A$14.6M). The management team averages 1.3 years in tenure, suggesting recent changes, while the board has more experience with an average tenure of 8.4 years. Get an in-depth perspective on Core Lithium's performance by reading our balance sheet health report here. Understand Core Lithium's earnings outlook by examining our growth report. PolyNovo Simply Wall St Financial Health Rating: ★★★★☆☆ Overview: PolyNovo Limited designs, manufactures, and sells biodegradable medical devices in the United States, Australia, New Zealand, and internationally with a market cap of A$832.47 million. Operations: The company generates revenue of A$115.58 million from the development, manufacturing, and commercialisation of its NovoSorb Technology. Market Cap: A$832.47M PolyNovo, with a market cap of A$832.47 million, has demonstrated significant earnings growth of 270.2% over the past year, surpassing its 5-year average and industry benchmarks. The company's recent sales report shows revenue climbing to A$118.6 million for Fiscal Year 2025, a notable increase from the previous year. Despite this growth, PolyNovo's management team is relatively inexperienced with an average tenure of 1.6 years, and it faces challenges such as negative operating cash flow and low return on equity at 7.8%. However, strong short-term assets cover both short-term and long-term liabilities effectively. Navigate through the intricacies of PolyNovo with our comprehensive balance sheet health report here. Gain insights into PolyNovo's outlook and expected performance with our report on the company's earnings estimates. Where To Now? Discover the full array of 450 ASX Penny Stocks right here. Contemplating Other Strategies? Trump's oil boom is here — pipelines are primed to profit. Discover the 22 US stocks riding the wave. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include ASX:BKY ASX:CXO and ASX:PNV. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
7 hours ago
- Yahoo
3000 jobs cut in $12 billion wipeout
Australia's largest pharmaceutical company could cut nearly 3000 jobs from its workforce as it looks to reduce its headcount across a number of businesses. The biggest shake up of the business in decades will see nearly 15 per cent of the global workforce reduced in a move aimed at 'simplifying the business.' Currently CSL employs about 30,000 staff globally. CSL said the one-off restructure would cost the business $770m pre tax before saving $500 to $550m over the next three years. The business said it would use these savings to invest in 'high priority' opportunities. Its share price dropped 11.15 per cent off the back of Tuesday morning's news — wiping roughly $12 billion off the company's market cap. CSL also announced its intention to demerge its influenza prevention vaccines-focused unit known as Seqirus into a separate ASX listed business in 2026. Gordon Naylor, a former president of CSL Seqirus, will run the new business. It will also combine the commercial and medical operations of its core blood plasma and iron deficiency businesses into one unit. The remaining CSL group will continue to have positions in multiple rare and serious diseases. The demerger will be subject to third party consents, regulatory approvals and CSL will conduct a voluntary shareholder vote. It has been tough 12 months for CSL, with the business facing unpredictable tariffs on its exports to the United States. On August 6 US President Donald Trump announced the first 'small tariff' on foreign-made drugs. 'We'll be putting (an) initially small tariff on pharmaceuticals,' Mr Trump told US business news channel CNBC. 'In one year, one-and-a-half years maximum, it's going to go to 150 per cent and then it's going to go to 250 per cent because we want pharmaceuticals made in our country.' He did not say what the initial rate would be, but earlier in the year he said duties on the sector would start from 25 per cent. Mr Trump said he is lifting prices as he wants to make American drugs cheaper for locals. CSL on Tuesday announced a 14 per cent increase in full-year underlying profits, up to $US3.3bn ($5.1bn) which was at the top of its forecasts. eToro market analyst Josh Gilbert said while the restructing comes with a sizeable one off cost, the move is expected to sharpen the group's focus on its high-growth plasma and kidney care business. 'For investors, the view here is that CSL is trying to create a clearer business structure and improve investor returns. However, markets hate uncertainty, and this shake-up brings plenty of it,' he said. 'These are huge changes that come with execution risk, and in my view, the market will react poorly to the news short term.' Mr Gilbert said CSL overall delivered a 'solid' full-year result with net profit ahead of expectations. 'But the real headline isn't the profit beat, it's the sweeping shake-up announced alongside it. As part of a major reset, CSL will reduce its workforce by around 15 per cent, close underperforming plasma centres, and spin off its Seqirus vaccine arm to list separately on the ASX by the end of the fiscal year,' he said. CSL chief executive officer Paul McKenzie said the business recognises a dynamic global backdrop, competitive pressure and organisation complexity have challenged CSL and hindered its ability to deliver superior returns. 'CSL Seqirus continued to show the resilience of its differentiated portfolio and platforms by generating growth in a challenging environment,' he said. 'The majority of avian flu contracts globally were awarded to CSL Seqirus, which was strong recognition of our best-in-class, differentiated platforms.'
